anorexia-cachexia

anorexia-cachexia

 
a systemic response to cancer occurring as a result of metabolites which may be produced by the tumor cells and released into the blood stream, stimulating the satiety center in the hypothalamus and producing appetite loss, gross alterations of metabolic patterns, and a profound systemic confusion which may result in further anorexia. This leads to malnutrition, weight loss, muscular weakness, and a negative nitrogen balance that contributes to the development of cachectic wasting.
References in periodicals archive ?
NGM is evaluating the potential of NGM120, an antagonistic antibody binding GFRAL, as a potential treatment of cancer anorexia-cachexia syndrome (CACS).
Anamorelin had some positive effects to relieve cancer anorexia-cachexia syndrome (CACS) and improve the quality of life (QoL).
Bort-Marti, "Megestrol acetate for treatment of anorexia-cachexia syndrome," Cochrane Database of Systematic Reviews, vol.
Beyond anorexia-cachexia. Nutrition and modulation of cancer patients' metabolism: supplementary, complementary or alternative anti-neoplastic therapy?
Ghrelin and GHSR have been used as the targets for treating many diseases such as cancer anorexia-cachexia, functional gastrointestinal disorders, and malnutrition, even prolonging the survival of patients with age-related syndromes [2,3,17,18].
As compared to participants without weight loss, study participants with weight loss reported significantly lower overall quality of life, worsened anorexia-cachexia symptoms and concerns, and higher symptomology, specifically fatigue, nausea and appetite loss.
Cancer anorexia-cachexia syndrome: current issues in research and management.
Meguid, "Cancer anorexia-cachexia syndrome: cytokines and neuropeptides," Current Opinion in Clinical Nutrition and Metabolic Care, vol.
Anamorelin is a new first-in-class, oral, once daily drug, presently in phase III for the treatment of anorexia-cachexia in NSCLC, a detrimental multifactorial disorder that affects more than 50 percent of people with cancer and in which systemic inflammation, reduced food intake and altered metabolism contribute to loss of muscle mass and reduction of body weight leading to reduced quality of life, functional impairment and decreased survival.
(22) Cytokines have been reported to influence the balance of orexigenic and anorexigenic circuits that predispose to cancer anorexia-cachexia syndrome.
Management of anorexia-cachexia associated with cancer and HIV infection.